Xintela AB
Xintela AB is a biotechnology company focused on healthcare diagnostics, primarily generating revenue through the development and commercialization of diagnostic solutions.
Business. Xintela AB (XINT.ST) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Xintela AB (XINT.ST) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Xintela AB operates with a negative equity position of -5.27 million SEK and a cash and equivalents balance of 23.21 million SEK, indicating a liquidity cushion despite a negative net income of -48.56 million SEK. The company's market capitalization is 196.37 million SEK, with a market price of 0.228 SEK per share. The enterprise value to revenue ratio is 75.88, suggesting a high valuation relative to its revenue of 2.28 million SEK.
Profitability metrics reveal a challenging financial position. The company's return on equity is 9.21%, which is unusually high given the negative net income, likely due to the negative equity base. The return on assets is -1.67%, indicating that the company is not generating returns from its asset base. The operating income is -46.68 million SEK, and the operating cash flow is -41.62 million SEK, highlighting significant operational losses.
Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data. However, the lack of segmental breakdown suggests a potential risk of over-reliance on a single product or market. The absence of capital expenditures indicates that the company is not investing in new projects or infrastructure, which could limit future growth.
The company's growth trajectory is constrained by its current financial performance. The revenue of 2.28 million SEK is not accompanied by positive growth indicators, and the outlook for the current and next fiscal years does not show improvement. The company's negative operating cash flow and free cash flow of -41.62 million SEK and -47.96 million SEK, respectively, suggest ongoing cash burn without clear signs of a turnaround.
Risk factors include a low liquidity position, as indicated by the current ratio of 0.84, and a negative equity position. The company has no immediate filing-based liquidity or dilution flags, but the negative net income and operating cash flow pose ongoing risks. The dilution potential is low, and no adjustments have been applied to the valuation metrics.
Recent events and filings do not indicate any significant changes in the company's strategic direction or financial status. The absence of recent capital raising activities or major business developments suggests a period of operational stagnation.
- Xintela AB is a biotechnology company with a negative equity position and significant operational losses.
- The company's high enterprise value to revenue ratio suggests a speculative valuation.
- The lack of capital expenditures and segmental revenue breakdown indicates limited diversification and growth potential.
- The company's liquidity position is weak, with a current ratio below 1 and negative net income.
- No immediate dilution or liquidity flags are present, but ongoing cash burn remains a concern.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Xintela AB Market data — financials · 2026-05-30
Ownership & reference
Leadership
- Greg BatchellerExecutive Chairman of the Board